Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

4.560 +0.310 (+7.29%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 Next >
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Reports First Quarter 2025 Financial Results and Provides Business Update
From Recursion Pharmaceuticals
Via GlobeNewswire
Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th
Company plans to host update call on Nov 20, 2024 after the anticipated close of the proposed business combination with Exscientia 
From Recursion Pharmaceuticals
Via GlobeNewswire
Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:TEM),(NASDAQ:POAI),(NASDAQ:ADMA) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th
Company to host public (L)earnings call on May 5th at 8:00 am ET / 6:00 am MT / 1:00 pm GMT 
From Recursion Pharmaceuticals
Via GlobeNewswire
Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth
From FN Media Group LLC
Via GlobeNewswire
Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas
REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitors 
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion to Participate in Upcoming Investor Conference
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th
Company to host public (L)earnings call on February 28th at 8:30 am ET / 6:30 am MT / 1:30 pm GMT 
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun
Dr. Bumpus brings deep experience in scientific innovation and regulatory strategy, while Elaine Sun adds extensive leadership in life sciences finance and corporate strategy. 
From Recursion Pharmaceuticals
Via GlobeNewswire
Altitude Lab Launches Pre-seed Venture Fund, Anchored by Recursion CEO Chris Gibson, Enabling SBIR-awarded Biotechs Hit by Funding Gap to Build in Salt Lake City
The Altitude Lab Fund aims to deliver strong returns to Limited Partners, accelerate the growth of Salt Lake City’s Life Science hub, and enable high potential startups support while federal funding is... 
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Altitude Lab Startups Raise $154M in Capital
The Accelerator Awards $150,000 Fellowship to Elnora AI CEO, and Announces Key Cohort Milestones 
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion to Present at 43rd Annual JP Morgan Healthcare Conference
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Artificial Intelligence (AI) Redefining Medical Diagnostics Industry That’s Expected to be a $7.2 Billion Market by 2029
EQNX::TICKER_START (OTCQB:AVAI),(OTCQX:RHHBY),(NASDAQ:RXRX),(NASDAQ:TEM),(NASDAQ:ISRG) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Recursion and Exscientia Shareholders Approve the Proposed Combination
Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close 
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden
OpenPhenom is a non-commercial, publicly available foundation model built on microscopy data that has set the new "gold standard" outperforming CellProfiler 
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the potential treatment... 
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.